A total of 167 human immunodeficiency virus (HIV) -infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily). At day 14, 87% of the fluconazoletreated patients were clinically cured, as opposed to 52% in the nystatin-treated group (P õ .001). Fluconazole eradicated Candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (P õ .001). The fluconazole group had fewer relapses noted on day 28 (18%, vs. 44% in the nystatin group; P õ .001). This relapse difference no longer existed by day 42. Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.
In the 1980s the rates of oropharyngeal candidiasis (oral Patients and Methods thrush) increased ú4-fold, and those of disseminated candidia-A total of 167 patients were enrolled in the study. Eligible sis increased ú10-fold [1] . Oropharyngeal and esophageal canpatients (1) met the criteria of the Centers for Disease Control didiasis are the most frequently diagnosed opportunistic infecand Prevention for a diagnosis of AIDS or had serological tions in the immunocompromised host [2 -4] . Oral candidiasis evidence of HIV infection and (2) had typical signs and sympoccurs in ú90% of patients with AIDS at some time during toms of oropharyngeal candidiasis. Diagnosis was confirmed their illness [5] . These infections can be severe, are usually in all cases by the presence of typical pseudohyphae or hyphae recurrent, are a marker of the severity of immunosuppression forms, which were identified in a swab or scraping specimen [6] , and are linked to the progression of AIDS [7] . The presence from an oral lesion or area of erythema; identifications were of thrush in the absence of predisposing factors may be the confirmed by mycologic culture. Patients with signs or sympfirst clue to the diagnosis of HIV infection. A burning sensation, toms of esophagitis were excluded from the study unless local pain and discomfort, and loss of taste are common sympesophagoscopy results were negative. Informed consent was toms of this infection.
obtained from all participants. Oral candidiasis has been treated most often with topical Patients who were taking other forms of antifungal therapy agents such as nystatin and clotrimazole, but few comparative at or within 3 days of enrollment (baseline) were excluded, clinical trials have been performed. In a previous study we as were patients who had a known history of intolerance to found no significant differences between the efficacy of oral imidazoles, triazoles, or the polyene components of nystatin. fluconazole tablets and clotrimazole troches, both of which Patients who concomitantly received phenytoin, oral hypoglywere highly effective in treating oral candidiasis [8] .
cemic therapy, coumarin-type anticoagulants, and cyclosporine This randomized prospective multicenter study was designed were allowed to participate but required ongoing monitoring to evaluate and compare the efficacy and toxicity of oral liquid during the study. fluconazole suspension, given once daily, with those of liquid Additional exclusion criteria included an inability to tolerate nystatin, given four times daily as a swish-retain-swallow regioral medications, the presence of moderate or severe liver dismen, in the treatment of oral candidiasis in HIV-infected paease (i.e., an aspartate aminotransferase, alanine aminotransfertients. ase, or alkaline phosphatase level ú3 times the upper limit of normal; a bilirubin level of ú3 mg/dL; or a partial thromboplastin time of ú5 seconds over the control value and not correctable by vitamin K administration), life expectancy of sessments (determination of the complete blood cell count and ence of disease. When there was no change or the candidiasis progressed, the case was designated a treatment failure. levels of platelets, aspartate aminotransferase, alanine aminotransferase, bilirubin, serum creatinine, blood urea nitrogen, Mycologic cure or eradication was characterized by the absence of Candida species in cultures on day 14 (end of treatand alkaline phosphatase) were performed. Within 48 hours of enrollment, swab or scraping specimens of lesions in clinically ment). Colonization was defined by a Candida-positive culture in the absence of clinical disease. Mycologic failure was deinvolved oral mucosa were examined for the presence of pseudohyphae or hyphae, and specimens were cultured for Candida fined by a positive culture and the presence of clinical disease. Patients in whom clinical resolution or improvement was species. Patients with obvious clinical disease whose microscopy results were positive were allowed to begin therapy while noted on day 14 were seen for posttreatment follow-up on days 28 and 42. Patients who were clinically cured but had mycoculture results were awaited. Those whose cultures were negative were deemed inevaluable and eliminated from the study.
logic evidence of infection were also seen on the same followup schedule, but mycologic colonization was considered to Eligible patients were randomly assigned to receive either fluconazole oral suspension or nystatin oral suspension for 14 have occurred because of the failure of the study treatment to eradicate the Candida organisms. For patients in whom clinical days. Patients receiving fluconazole took 100 mg (10 mL) once daily for 14 days (with a 200-mg [20-mL] loading dose on day cure or improvement and mycologic cure were not achieved, treatment was designated as a failure, and these patients were 1), and patients receiving nystatin took 5 mL (500,000 U) four times daily for a total of 14 days. Patients receiving fluconazole withdrawn from the study. were instructed to swallow the suspension directly, at approximately the same time every day. Nystatin recipients were di-
Statistical Methodology
rected to swish and then retain each dose in the mouth for as long as possible before swallowing, as prescribed in the pack-
The primary study endpoint was clinical response to treatment, as expressed in the proportions of patients who were age insert for this drug.
Six evaluations took place during this study, on days 1, 3, clinically cured in both groups (with use of the Mantel-Haenszel x 2 test adjusted for study site). Tests were two-tailed and 7, and 14 (end of treatment) and days 28 and 42 (follow-up). At each visit any signs and symptoms of oral candidiasis were based on a .05 level of significance. Frequencies of relapse on or before follow-up visits (days 28 and 42) were also compared. noted. Oral sampling was repeated for microscopy and fungal culture on days 7 and 14. Swab and scraping specimens were obtained again on days 28 and 42 only if clinical lesions or Results erythema in the oropharynx reappeared. When no lesions were present, their absence was recorded. The clinical evaluator at Of the 167 patients enrolled in the study, 83 were randomly assigned to receive fluconazole and 84 to receive nystatin. In each study point was unaware of what drug the patient was taking.
both groups, the male:female ratio was 7:1 and the mean age was 38 years. The degree of severity of signs and symptoms of candidal infection at baseline for both treatment groups is
Efficacy Criteria
shown in table 1. No statistically significant differences in clinical manifestations were evident between groups at baseTo be considered evaluable for primary clinical efficacy, line. Of the enrolled patients, 69 fluconazole and 69 nystatin patients had to have mycologically confirmed, symptomatic recipients were evaluable for clinical outcome. Mycologic outoropharyngeal candidiasis at baseline. They had to have recome was evaluable in 68 fluconazole-treated patients and 66 ceived at least 5 days of therapy with fluconazole (five doses) nystatin-treated patients. or nystatin (20 doses). No other antifungal therapy was allowed Table 2 shows the clinical and mycologic outcome for the during the study. End-of-treatment culture and/or microscopic evaluable patients at the end of therapy and data on relapses examination was required for all participants.
noted on days 28 and 42. Twenty-nine patients (14 fluconazole Adverse events were assessed at each visit. Compliance with and 15 nystatin recipients) discontinued participation in the study protocol was assessed with use of drug administration study before day 14 and were not evaluated for efficacy: 16 records or by measuring the remaining suspension volume.
were lost to follow-up (8 fluconazole and 8 nystatin recipients), Laboratory evaluations were repeated on days 7 and 14. malities (2 fluconazole and 1 nystatin recipient), death unrelated the nystatin group (P õ .001). Eradication of Candida species was achieved by the end of treatment (day 14) in 41 of 68 to the study drug (1 nystatin recipient), or other reasons (12 fluconazole and 15 nystatin recipients).
fluconazole-treated patients (60%) vs. 4 of 66 nystatin-treated patients (6%) (P õ .001).
Relapses had occurred in both treatment arms by the time
Clinical and Mycologic Response
of the follow-up evaluations (days 28 and 42) (table 2). Although more patients remained disease-free in the fluconazole A total of 60 (87%) of the 69 evaluable patients in the fluconazole group were considered clinically cured, as opposed group at day 28, there were no statistically significant differences in relapse after day 28 between the two groups at the to 36 (52%) of 69 evaluable patients in the nystatin group. There were 8 clinical improvements and 1 treatment failure in end of the follow-up (day 42). Candida albicans accounted for 95% (128) of the 134 Candida isolates in baseline cultures the fluconazole group and 11 improvements and 22 failures in and 93% (83) of the 89 isolates representing colonization or failures. Most patients who have oral candidiasis have a clinically and mycologic cure rate of 60% for fluconazole oral suspension minor infection, and the topical agents such as clotrimazole and are remarkably similar and consistent with previously pubnystatin are typically used as treatment. This large, prospective lished results concerning use of fluconazole tablets [8] , a findcomparative study shows a statistically significant clinical difing suggesting equal efficacy for these two formulations of ference in outcome, with liquid nystatin clearly inferior to flufluconazole. The nystatin-treated group had poor outcomes in conazole oral suspension. The study indicates that when topical terms of both clinical (52%) and mycologic (6%) responses.
agents are used, liquid nystatin in a swish-retain-swallow regiPotential explanations for the differences in efficacy did not men is not an optimal treatment for oral candidiasis in patients appear to include compliance. The oral suspension form of with AIDS. fluconazole may have optimized the total drug exposure to the oral mucosa by both topical and systemic pharmacokinetics [9] . Differences in the antifungal activity of the drugs may also
